Retatrutide Research Protocol: Reconstitution, Dosing Schedule & Storage Guide
Research Context: This guide describes standard laboratory reconstitution and handling procedures intended for in vitro research applications only. All protocols are provided for scientific reference. Products referenced are not approved for human or animal use.
Retatrutide (LY3437943) is an investigational triple-receptor agonist currently in Phase 3 clinical development. It targets GLP-1, GIP, and glucagon receptors simultaneously — a mechanism that distinguishes it from every other compound in its class. Phase 2 data published in the New England Journal of Medicine reported up to 24% body weight reduction at 48 weeks in participants with obesity. Phase 3 TRIUMPH-4 data (2025) confirmed 28.7% average weight reduction at 68 weeks.
This retatrutide protocol guide covers the standard procedures for the 5mg vial: reconstitution, concentration math, dosing schedule, and storage requirements. All information is for research and educational purposes only. Retatrutide is not FDA-approved and is not intended for human use or consumption.
What Comes in the Vial
Each Magnolia RL Retatrutide vial contains 5mg of lyophilized (freeze-dried) retatrutide peptide. The powder must be reconstituted with bacteriostatic water before use in research protocols. Unreconstituted vials should be stored at −20°C (−4°F) — unlike most peptides, Retatrutide requires freezing, not refrigeration, for stable long-term storage.
Reconstitution
What you need:
- Retatrutide 5mg vial
- Bacteriostatic water (BAC Water)
- 1mL insulin syringe (U-100)
- Alcohol prep swabs
Protocol: Add 1.0mL of bacteriostatic water to each 5mg vial. This produces a concentration of 5.0mg/mL. Inject the BAC Water slowly down the inside wall of the vial — do not aim directly at the powder. Gently swirl until fully dissolved. Do not shake. The solution should be clear and colorless. Label the vial with the reconstitution date and refrigerate at 2–8°C (36–46°F). Reconstituted Retatrutide is stable for up to 4 weeks refrigerated. Do not freeze a reconstituted vial.
Reading the Syringe
On a standard U-100 insulin syringe: 100 units = 1.0mL; 1 unit = 0.01mL. At 5.0mg/mL concentration: 1 unit = 50mcg; 40 units (0.40mL) = 2mg; 80 units (0.80mL) = 4mg.
Dosing Schedule
Phase 2 and Phase 3 trials used a once-weekly subcutaneous administration protocol with gradual dose escalation over 8–12 weeks.
| Phase | Weekly Research Dose | Syringe Volume |
|---|---|---|
| Weeks 1–4 | 2mg | 40 units (0.40mL) |
| Weeks 5–8 | 4mg | 80 units (0.80mL) |
| Weeks 9–12 | 6mg | 60 units × 2 sites (1.20mL total) |
| Weeks 13+ | 8mg | 80 units × 2 sites (1.60mL total) |
How It Works: Triple Receptor Mechanism
GLP-1 receptor agonism suppresses appetite and enhances glucose-dependent insulin secretion — the same mechanism as semaglutide and tirzepatide. GIP receptor agonism enhances the incretin effect and complements GLP-1 activity. Glucagon receptor agonism increases basal metabolic rate and promotes hepatic fat oxidation — unique to Retatrutide among clinically studied compounds. Preclinical data confirmed that glucagon receptor activation counteracts the metabolic slowdown that typically accompanies significant weight loss.
Storage Summary
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (unreconstituted) | −20°C (−4°F) | Up to 24 months |
| Reconstituted | 2–8°C (36–46°F) | Up to 4 weeks |
This protocol is adapted from published Phase 2 and Phase 3 clinical trial data (Jastreboff et al., NEJM 2023; TRIUMPH-4, 2025). All Magnolia RL products are for in vitro research use only. Not for human or veterinary use.